Building a Healthier Future Together: Strengthening Cancer Care Across Africa Through Partnership

NORTHAMPTON, MA / ACCESS Newswire / December 17, 2025 / Originally published on Bristol Myers Squibb News & Perspectives

For many cancer patients throughout Africa, the journey to diagnosis and treatment can be long and uncertain. But across the continent, communities and local leaders are working to change that reality. The Bristol Myers Squibb Foundation (BMS Foundation), an independent charitable organization, is proud to support many of these changemakers by strengthening cancer care systems and improving access to quality care, closer to home.

Recently, BMS Foundation President Catharine Grimes and members of the BMS Foundation team traveled to Africa to witness firsthand the impactful work of their grantee partners and meet with patients in various communities. The trip highlighted the profound impact of local efforts to transform health outcomes, and the unwavering commitment of the people working tirelessly to improve and save lives.

Their journey began in Kitui County, Kenya, where cervical and breast cancer are the leading causes of death among women of reproductive age, and access to treatment locally was once virtually unattainable. For years, patients had to travel over 150 miles to Nairobi for specialty care, often sleeping in hospital corridors. But today, the Phangisile Mtshali Cancer Center stands as a beacon of hope. Established in partnership with the Centre for Medical Mobilisation Board (CMMB) and the Kitui County Ministry of Health, the center has served more than 600 new patients and recorded over 5,400 revisits in just two years. It has also served as a hub for coordinating life-saving public health interventions, including reaching over 36,500 girls aged 10-14 with the HPV vaccine as a critical step toward advancing the WHO's 90-70-90 cervical cancer elimination strategy.

"The Phangisile Mtshali Cancer Center has become a lifeline for cancer patients in Kitui county," said Grimes. "Survivors bravely shared their stories with us, and they spoke with deep gratitude for this center that has changed their lives. It reaffirmed for us that when care is close to home, everything changes - outcomes, trust and lives. That is the power of building strong local systems that are responsive to the needs of the community."

The BMS Foundation next traveled to Kisumu County, joining grantee partner Cure Cervical Cancer Kenya's Mobile Health for Mamas program. Their community health campaign model uses home-based human papillomavirus (HPV) self-sampling, mobile treatment outreaches where eligible HPV-positive women who receive same-day diagnosis are invited for visual inspection with acetic acid (VIA) and are offered free thermal ablation treatment and patient navigation services.

"This initiative is grassroots public health at its finest," Grimes shared. "Women from remote areas are able to access critical screening and treatment, and they are cared for with compassion and respect. The commitment of these health workers is nothing short of inspiring."

Since 2021, the program has screened over 47,000 women for HPV and treated more than 8,000 HPV-positive patients in Kenya.

That same commitment to community-led, patient-centered care was on full display as the Foundation team continued on to other grantee sites. In Durban, South Africa, they participated in the Cancer & Infectious Diseases Epidemiology Research Unit-University of KwaZulu Natal's (CIDERU-UKZN) mobile X-ray outreach in one of the implementing sites, which was made possible in collaboration with other CIDERU-UKZN partners, showcasing the power of inclusive interventions at the community level. They also toured the newly renovated lung cancer unit at Addington Hospital, which is focused on reducing the proportion of patients being diagnosed with lung cancer in stages 3 & 4 and increasing the volume of patients being diagnosed at earlier stages (1 & 2), ultimately saving lives.

And at the CANSA Mkhuhla Care Home, they met patients who received housing, meals, counseling and a supportive community after traveling long distances for treatment.

In Eldoret, Kenya, at the Moi Teaching and Referral Hospital (MTRH) in Uasin-Gishu County, the team made a visit to one of the facilities, Kamalel Health Centre in Kesses Sub-County. They witnessed local efforts to build community awareness, improve early detection and connect patients to treatment through navigation and peer support.

One patient, Martin Ijakaa, shared how the program not only connected him to treatment, but also restored his sense of dignity. Mr. Ijakaa had experienced vision loss and severe neurological symptoms but received no treatment plan or support despite visiting various facilities outside MTRH, including the capital Nairobi. He was ultimately reached by a patient navigator from the BMS Foundation supported project, Academic Model Providing Access to Healthcare Multinational Lung Cancer Control Program (AMPATH MLCCP). After evaluation, procedures for biopsy and access to critical diagnostic tests, he was diagnosed with stage IV lung adenocarcinoma. He received appropriate management that included radiotherapy and a targeted therapy - as well as complementary support through home visits, peer support groups and counseling. Today Martin continues to do well, enjoying life and his family.

"Meeting Martin reminded us that behind every initiative is a human story," said Grimes. "There is a story of struggle, but also of resilience. Martin's journey reminds us why this work matters. Our partners are giving their patients a reason to believe in tomorrow."

The Africa Grantee Summit: Learning, connection and shared purpose

These site visits set the stage for the BMS Foundation's annual Africa Grantee Summit in Johannesburg, where grantee partners from across the continent convened to share progress, challenges, and opportunities to continue to grow their programs. Sessions focused on evaluation, research readiness, community-based innovation and sustainability, and provided the opportunity for celebration, collaboration and unity around shared purpose.

Joining Grimes was Bristol Myers Squibb Foundation Board Member and Bristol Myers Squibb Executive Vice President, Corporate Affairs, Wendy Short Bartie, whose presence underscored sustained commitment to the work.

"The BMS Foundation's ethos is to put patients and people first, and to act with conviction to change outcomes where the need is greatest," said Bartie. "That commitment is evident in the grantee partnerships it has established. The work being done across Africa shows that, even in the face of enormous challenges, it is possible to create lasting change and develop solutions that transform health outcomes and save lives."

Renewed commitment: Post-Summit site visits

Following the Grantee Summit, Bartie and Grimes embarked on more grantee partner visits in South Africa. At the Wits Lung Laboratory in Helen Joseph Hospital, they met Dr. Anita Graham, who in 2018 established a unit that now provides services in diagnosis, staging, management and palliative care, shifting the outlook on lung cancer in South Africa to equitable, advanced and consistent care. They joined a community outreach event with Afia Tai at an informal settlement without a primary healthcare clinic, where Afia Tai's team provided cervical cancer screening services to local women and introduced them to members of its cancer support group for patients and their families. And at the Soweto Comprehensive Cancer Centre (SCCC) at Chris Hani Baragwanath Academic Hospital, Chief Executive Officer Dr. Nthabiseng Makgana shared how adult oncology and palliative care units and a new smoking cessation support group - one of the few structured cessation programs operating on the continent - are transforming local care. Smoking cessation programs are exceptionally rare across Africa, and the BMS Foundation grant to the SCCC is bringing this evidence-based, preventive service and assistance to people who are committed to quit smoking.

"What struck me most was the joy and hope we witnessed," Grimes said. "The support group wasn't just about quitting smoking. It was about rebuilding confidence, community and self-belief."

"Everywhere we went, we saw the same thing - courage in the face of adversity, hope where there was once none and a fierce determination to build a better future," added Bartie.

Looking ahead

While persistent challenges for access and equitable care in Africa remain, the BMS Foundation and its grantee partners are making significant strides to break down barriers and are building local health capacity, driving sustainable care that can transform the lives of patients and their families.

"Expanding access to high-quality care in partnership with local leaders is at the core of our mission," said Grimes. "There is more to be done, but we are already seeing the difference these collaborations are making in the lives of patients and families."

Photo: BMS Foundation Africa Grantee Summit

View additional multimedia and more ESG storytelling from Bristol-Myers Squibb Company on 3blmedia.com.

Contact Info:
Spokesperson: Bristol-Myers Squibb Company
Website: https://www.3blmedia.com/profiles/bristol-myers-squibb-company
Email: info@3blmedia.com

SOURCE: Bristol-Myers Squibb Company



View the original press release on ACCESS Newswire

News Provided by ACCESS Newswire via QuoteMedia

BMY
The Conversation (0)
Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retirement Income Security Act of 1974

Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retirement Income Security Act of 1974

Lawsuits have been filed alleging that a number of large corporate employers have offloaded billions of dollars in pension obligations to Athene Annuity and Life Company andor Athene Annuity & Life Assurance Company of New York, subsidiaries of Athene Holding Ltd. (collectively, "Athene") in... Keep Reading...
Bristol Myers Squibb Reports First Quarter Financial Results for 2023

Bristol Myers Squibb Reports First Quarter Financial Results for 2023

Reports First Quarter Revenues of $11.3 Billion Posts First Quarter GAAP Earnings Per Share of $1.07 and Non-GAAP EPS of $2.05; Includes Net Impact of ($0.01) Per Share for GAAP and Non-GAAP EPS Due to Acquired IPRD Charges and Licensing Income Delivers Strong Revenue Growth of 8% from In-Line... Keep Reading...
Bristol Myers Squibb Announces Leadership Transition Plan

Bristol Myers Squibb Announces Leadership Transition Plan

Giovanni Caforio, MD, Bristol Myers Squibb Chairman and CEO, to Retire as CEO, Effective November 1, 2023; Will Continue as Executive Chairman of the Board Christopher Boerner, PhD, EVP, Chief Commercialization Officer, Appointed EVP, Chief Operating Officer, Effective Immediately; to Succeed... Keep Reading...
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS®  for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS® for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy

If approved, CAMZYOS would be the first cardiac myosin inhibitor in Europe that specifically targets the source of obstructive HCM Recommendation based on positive Phase 3 EXPLORER-HCM and VALOR-HCM trials demonstrating benefit in patients receiving CAMZYOS versus placebo Bristol Myers Squibb... Keep Reading...
Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production

Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production

Libertyville, Illinois facility bolsters long-term viral vector supply with multi-product, in-house viral vector production capabilities Bristol Myers Squibb (NYSE: BMY) today announced expansion of its global cell therapy manufacturing network to enable in-house viral vector production through... Keep Reading...
Quantum Biopharma

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Reward to be Paid if Information Contributes Significant Evidence Leading to a Trial Victory or Settlement in Landmark USD $700 Million+ Lawsuit

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol... Keep Reading...
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and... Keep Reading...
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare. But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no... Keep Reading...
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This... Keep Reading...
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access... Keep Reading...
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will... Keep Reading...

Interactive Chart

Latest Press Releases

Related News